B of A Securities Downgrades SQZ Biotechnologies to Underperform, Lowers Price Target to $2
B of A Securities analyst Tazeen Ahmad downgrades SQZ Biotechnologies (NYSE:SQZ) from Buy to Underperform and lowers the price target from $9 to $2.